A prática da hidroginástica como tratamento complementar para pacientes com transtorno de ansiedade The practice of hydrogymnastics as a complementary treatment for patients with anxiety disorders

OBJETIVO: Analisar a efetividade da hidroginástica, como auxiliar terapêutico à redução do nível de ansiedade, em mulheres diagnosticadas com transtorno de ansiedade. MÉTODOS: Este ensaio clínico teve a participação de pacientes com ansiedade, sendo a depressão a comorbidade existente, do programa de Residência Médica em Psiquiatria do Hospital Universitário de Maringá, todas em tratamento com medicamentos (n = 16: grupo experimental = 8; grupo-controle = 8). O experimento foi realizado na piscina aquecida do Departamento de Educação Física da Universidade Estadual de Maringá. O delineamento do estudo foi elaborado com duas sessões de hidroginástica por semana, durante 12 semanas. Os instrumentos utilizados foram: o Inventário de Ansiedade de Beck (BAI) e o Perfil de Estado de Humor (POMS). Para análise estatística, foram utilizados o teste de Friedman, o Teste de Wilcoxon, o Teste de Mann-Whitney e Comparações Múltiplas, adotando significância em 5%. RESULTADOS: Os escores do transtorno de ansiedade tiveram redução no grupo experimental, após 12 semanas de intervenção (19,12 ± 3,12 para 8,37 ± 4,60 pontos, P = 0,0005*), e no grupo-controle (17,87 ± 14,32 para 12,12 ± 9,58 pontos, P = 0,254). Para o perfil do estado de humor, o grupo experimental evidenciou perfil de saúde mental positiva, enquanto o grupo-controle demonstrou perfil negativo de estado de humor. CONCLUSÕES: Portanto, as pacientes do grupo experimental evidenciaram significativa redução do nível de ansiedade em relação às pacientes do grupo-controle, que utilizaram apenas o tratamento convencional com medicamentos. Para o perfil do estado de humor, foram encontradas alterações no decorrer do estudo; o grupo-controle experimentou alteração negativa de humor durante o ensaio clínico, enquanto os pacientes do grupo experimental evidenciaram perfil positivo de estado de humor com redução da tensão, depressão, raiva, confusão e aumento do vigor.<br>OBJECTIVE: To analyze the effectiveness of hydrogymnastics as a therapeutic method to the reduction of anxiety in females diagnosed with anxiety disorder. METHODS: This clinical survey had as participants, patients with anxiety, being the depression the existent comorbidade, from Psychiatry Media Residence Program of the Academical Hospital of Maringá, all had medical treatment (n = 16: experimental group = 8; control group = 8). The experiment was accomplished in the warm swimming pool of the Department of Physical Education of the State University of Maringá. The design of the study was developed with two hydrogymnastics sessions per week, during 12 weeks. The instruments used in the data collection were: Beck's Anxiety Inventory (BAI) and the Profile of Mood States (POMS). As to statistics analysis the Friedman test, Wilcoxon test, Mann-Whitney test and Multiple Comparisons were used, with a significance of 5%. RESULTS: Results show that anxiety disorder scores decreased in the experimental group after 12 weeks of intervention (19.12 ± 3.12 to 8.37 ± 4.60, P = 0.0005*) and control group (17.87 ± 14.32 to 12.12 ± 9.58, P = 0.254). As for mood state profile experimental group evidenced a positive mental health profile, while control group showed a negative mood state profile. CONCLUSIONS: It may be concluded that patients from experimental group evidenced significant reduction in anxiety level in relation to control group patients whom used only the conventional medicine treatment. For mood state profile changes were found throughout the study, being that control group experimented negative mood changes during the clinical survey while experimental group patients evidenced positive mood state profile with reduction on tension, depression, anger confusion and enhancement on vigor

Ezetimibe added to statin therapy after acute coronary syndromes

BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit